Once-daily IV-to-oral NUZYRA safe and effective in adults with pneumonia and skin infections, demonstrating clinical activity against relevant pneumonia- and skin-associated drug resistant bacteria
BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced The New England Journal of Medicine (NEJM) today published detailed results from the OPTIC and OASIS-1  Phase 3 clinical trials of NUZYRA™ (omadacycline).

NUZYRA is a modernized tetracycline that is a once-daily intravenous (IV) and oral for the treatment of comm…

READ FULL TEXT